tranScrip
Rob Fox currently serves as Chief Commercial Officer at tranScrip since January 2025. Prior to this role, Rob Fox held multiple positions at Clinigen from June 2015 to December 2024, including VP Corporate Development and VP Investor Relations and Corporate Development, where responsibilities included formulating M&A strategies, managing investor relations, and overseeing corporate communications. Rob Fox also previously led global business development efforts at Idis from 2003 until its acquisition by Clinigen, where leadership included defining Managed Access strategies and overseeing international business teams for pharmaceutical and biotech partners. Rob Fox holds a BA Hons in Business Economics from the University of Liverpool, earned between 1995 and 1998.
This person is not in any teams
This person is not in any offices
tranScrip
tranScrip is a leading contract drug development organisation which supports pharma and biotech companies in the development and lifecycle of medicines. We bring innovative solutions to clients’ global drug development needs. From translational medicine through to registration and post licencing, we deliver both strategic leadership and operational execution of development programmes, covering clinical, regulatory, drug safety, and commercial elements. Our teams of physicians, scientists and regulatory experts, help clients select the most promising drug candidates and bring them to the market. We guide our clients through their decision making from first in man studies to proof of concept and pivotal trials, regulatory submissions and product launches. In the last decade, tranScrip has supported over 250 clients and has been integral to many development programmes and regulatory submissions, bringing products to the market each year across a wide range of therapeutic areas.